Drug Profile
Research programme: dendrophilins - Innaxon
Alternative Names: Dendrophilin Novo-PyrexalLatest Information Update: 30 Aug 2023
Price :
$50
*
At a glance
- Originator Innaxon
- Class Antineoplastics; Lipopolysacchrides
- Mechanism of Action Toll-like receptor 4 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 30 Aug 2023 Preclinical development is ongoing in United Kingdom (Innaxon pipeline, August 2023)
- 01 Aug 2016 Research programme: dendrophilins - Innaxon is available for licensing - https://innaxon.com/aboutus
- 22 Feb 2016 Preclinical trials in Cancer in United Kingdom (unspecified route)